CD274 and metabolic dysfunction-associated steatotic liver disease: To specifically characterize the effect of anti-PD(L)1 immunotherapy with respect to underlying liver disease, we investigated a cohort of 130 patients with HCC (patients with NAFLD n = 13; patients with other aetiologies n = 117) (Supplementary Table 8).